Table 2.
The clinical characteristic information of patients from the validation cohort with ccRCC in The Cancer Genome Atlas database related genes.
| Validation | TCGA-KIRC | High risk score | Low risk score |
|---|---|---|---|
| Cohort | (n = 200) | (n = 100) | (n = 100) |
| Number of patients | 531 | 266 | 265 |
| T_Stage | |||
| T1 | 111 (55.50%) | 46 (46.00%) | 65 (65.00%) |
| T2 | 28 (14.00%) | 14 (14.00%) | 14 (14.00%) |
| T3 | 59 (29.50%) | 38 (38.00%) | 21 (21.00%) |
| T4 | 2 (1.00%) | 2 (2.00%) | 0 (0.00%) |
| N_Stage | |||
| N0 | 90 (45.00%) | 43 (43.00%) | 47 (47.00%) |
| N1 | 3 (1.50%) | 3 (3.00%) | 0 (0.00%) |
| NX | 107 (53.50%) | 54 (54.00%) | 53 (53.00%) |
| M_Stage | |||
| NA | 1 (0.50%) | 1 (1.00%) | 0 (0.00%) |
| M0 | 160 (80.00%) | 74 (74.00%) | 86 (86.00%) |
| M1 | 27 (13.50%) | 18 (18.00%) | 9 (9.00%) |
| MX | 12 (6.00%) | 7 (7.00%) | 5 (5.00%) |
| Stage | |||
| Stage I | 109 (54.50%) | 45 (45.00%) | 64 (64.00%) |
| Stage II | 24 (12.00%) | 13 (13.00%) | 11 (11.00%) |
| Stage III | 38 (19.00%) | 22 (22.00%) | 16 (16.00%) |
| Stage IV | 29 (14.50%) | 20 (20.00%) | 9 (9.00%) |
| OS | |||
| Mean | 1353.58 | 1222.73 | 1484.42 |
| Median | 1109.00 | 992.00 | 1409.00 |
| Age | |||
| ≤ 60 | 107 (53.50%) | 52 (52.00%) | 55 (55.00%) |
| > 60 | 93 (46.50%) | 48 (48.00%) | 45 (45.00%) |
| Gender | |||
| Female | 69 (34.50%) | 34 (34.00%) | 35 (35.00%) |
| Male | 131 (65.50%) | 66 (66.00%) | 65 (65.00%) |